Article Data

  • Views 744
  • Dowloads 119

Original Research

Open Access

Effects of docetaxel combined with radiotherapy on immune function, tumor marker indices, and suppression of gene inactivation in breast cancer patients

  • Ying Yu1
  • Cong Long1
  • Li Ding1
  • Gong Zhang2,*,

1Clinical Laboratory, Jingjiang People’s Hospital, 214500 Taizhou, Jiangsu, China

2General Surgery, Jingjiang People’s Hospital, 214500 Taizhou, Jiangsu, China

DOI: 10.22514/ejgo.2024.016 Vol.45,Issue 1,February 2024 pp.106-115

Submitted: 26 September 2023 Accepted: 06 December 2023

Published: 15 February 2024

*Corresponding Author(s): Gong Zhang E-mail: 18652727157@163.com

Abstract

This study aimed to investigate the clinical efficacy of combining docetaxel with radiotherapy in breast cancer patients who have undergone surgery. 110 breast cancer patients admitted to our hospital were selected between January 2023 and June 2023 and randomly allocated into two groups (n = 55/group) using a randomized numerical table method. After surgery, the control group received docetaxel, while the study group received docetaxel in conjunction with X-ray intensity-modulated radiation therapy. Their clinical effectiveness, tumor markers, DNA methyltransferase (DNMT1), oncogene cripto-1 (CP-1), and CUE structural domain protein 2 (CUEDC2) expression levels and adverse events were compared before and after treatment. After treatment, we found no significant differences in T lymphocyte subpopulation indices between the two groups (p > 0.05), while the study group had significantly lower levels of all tumor markers, including DNMT1, CP-1 and CUEDC2, compared to the control group (p < 0.05). The incidence of adverse events in the study group (9.09%) was slightly higher than in the control group (5.45%), but the difference was not statistically significant (p > 0.05). In summary, postoperative docetaxel combined with X-ray intensity-modulated radiotherapy may lower tumor marker levels, inhibit malignant tumor cell behavior, enhance overall clinical efficacy, and extend patient survival without significantly impacting immune function or increasing the risks of adverse effects.


Keywords

Docetaxel; Radiotherapy; Breast cancer patients; Immune function; Tumor markers; Inhibiting gene inactivation


Cite and Share

Ying Yu,Cong Long,Li Ding,Gong Zhang. Effects of docetaxel combined with radiotherapy on immune function, tumor marker indices, and suppression of gene inactivation in breast cancer patients. European Journal of Gynaecological Oncology. 2024. 45(1);106-115.

References

[1] Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, et al. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cellular and Molecular Life Sciences. 2022; 79: 539.

[2] Köksal M, Hoppe C, Schröder A, Scafa D, Koch D, Sarria GR, et al. Decision regret in breast cancer patients after adjuvant radiotherapy. The Breast. 2023; 68: 133–141.

[3] Dane B, Doshi A, Gfytopoulos S, Bhattacharji P, Recht M, Moore W. Automated radiology-pathology module correlation using a novel report matching algorithm by organ system. Academic Radiology. 2018; 25: 673–680.

[4] Warth B, Palermo A, Rattray NJW, Lee NV, Zhu Z, Hoang LT, et al. Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells. Metabolites. 2019; 9: 7.

[5] Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Jukkola A, Tanner M, Ahlgren J, et al. Adjuvant capecitabine for early breast cancer: 15-year overall survival results from a randomized trial. Journal of Clinical Oncology. 2022; 40: 1051–1058.

[6] Dover L, Dulaney C. Prostate stereotactic body radiation therapy margins, accelerated partial breast irradiation techniques, total neoadjuvant therapy local control, hyperfractionated reirradiation, hyaluronic acid rectal spacer, and concurrent docetaxel for head and neck cancer. Practical Radiation Oncology. 2023; 13: 267–272.

[7] Yan M, Yuan P, Ouyang Q, Cheng Y, Han G, Wang D, et al. A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer. Therapeutic Advances in Medical Oncologyd. 2022; 24: 17588359221122715.

[8] Ben Dhia S, Loap P, Loirat D, Vincent-Salomon A, Cao K, Escalup L, et al. Concurrent radiation therapy and dual HER2 blockade in breast cancer: assessment of toxicity. Cancer Radiother. 2021; 25: 424–431. (In French)

[9] Wang Y, Huang J, Wu Q, Zhang J, Ma Z, Ma S, et al. Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38. Investigational New Drugs. 2021; 39: 458–468.

[10] El Bakraoui K, El Morabit B. Orbital metastasis from triple-negative breast cancer: case report and literature review. Case Reports in Oncology. 2020; 13: 1042–1046.

[11] Luo Y, Ye Y, Chen Y, Zhang C, Sun Y, Wang C, et al. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer. Frontiers in Immunology. 2023; 14: 1140993.

[12] Trokic D, Marosevic G, Simeunovic V, Lekic S, Babic B, Gojkovic Z. High Ki67 as negative predictor for response to concurrent radiotherapy plus Capecitabine in chemo-resistant advanced breast cancer. Journal of B.U.ON. 2021; 26: 466–474.

[13] Wang X, Cong Y, Qiao G, Zhang S, Wang L. Primary breast cancer patient with poliomyelitis: a case report. World Journal of Clinical Cases. 2020; 8: 6190–6196.

[14] Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, et al. A case of breast cancer during pregnancy treated with neoadjuvant chemotherapy during pregnancy. Japanese Journal of Cancer and Chemotherapy. 2022; 49: 289–292. (In Japanese)

[15] Zhang X, Zhang Z, Cao M, Liu B, Mori M, Luoh S, et al. A randomized parallel controlled phase II trial of recombinant human endostatin added to neoadjuvant chemotherapy for stage III breast cancer. Clinical Breast Cancer. 2020; 20: 291–299.e3.

[16] Dos Santos RLB, Osorio-de-Castro CGS, Sobreira-da-Silva MJ, Pepe VLE. First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil. Frontiers in Pharmacology. 2023; 14: 1069505.

[17] Yamamuro M, Konishi J, Nozaki Y, Ueno M, Ishida T, Kamo N, et al. A case of lung metastasis of the breast cancer with a remarkable response to stereotactic body radiation therapy (SBRT). Japanese Journal of Cancer and Chemotherapy. 2020; 47: 1878–1880. (In Japanese)

[18] Srivastava N, Usmani SS, Subbarayan R, Saini R, Pandey PK. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Frontiers in Oncology. 2023; 13: 1199105.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top